The inflammatory bowel disease Crohn’s Disease (CD) is a chronic disorder with wounds along the GI-tract that requires lifelong therapy. The incidence rate of IBD, comprising CD and ulcerative colitis is highest in developed countries, afflicting nearly 4 million people worldwide, and with a prevalence of CD of up to 1% of people.

Oral ingestion is the predominant and most preferable route for drug delivery. However, the gastrointestinal tract (GI-tract) presents several barriers with the acidic environment of the stomach being the most challenging barrier. A new and innovative application is to use bacteria as delivery vectors of therapeutic proteins to surfaces of the GI-tract. The “generally recognized as safe” (GRAS)-bacterium Lactococcus has been used in the food industry for several decades and a certain strain will die when entering the small intestine whereby it destroys its own DNA.